

TRANSACTION REPORT

P. 01

MAR-25-2002 MON 02:43 PM

FOR: SALIWANCHIK, LLOYD&SALIWA 352 372 5800

DATE	START	RECEIVER	TX TIME	PAGES	TYPE	NOTE	M#	DP
MAR-25	02:40 PM	17038729306	2' 35"	5	SEND	OK	038	

TOTAL : 2M 35S PAGES: 5

FACSIMILE COVER SHEET

SALIWANCHIK, LLOYD & SALIWANCHIK

A Professional Association
2421 N.W. 41st Street
Suite A-1
Gainesville, FL 32606

Telephone (352) 375-8100
Facsimile (352) 372-5800

TO: Examiner Jeffrey Norman Fredman **FROM:** Frank C. Eisenschenk, Ph.D.

COMPANY: U.S. Patent Office, Art Unit 1655 **DATE:** March 25, 2002

FAX NO.: 1-703-872-9306

NO. OF PAGES:
(INCLUDING COVER SHEET)

5

SUBJECT/MESSAGE: U.S. Patent Application Docket No. GEN-T124X
GENES, PROTEINS AND BIALLELIC MARKERS RELATED OT
CENTRAL NERVOUS SYSTEM DISEASE
(Blumenfeld, *et al.*)
Serial No. 09/416,384; Filed October 12, 1999

THIS IS AN OFFICIAL DOCUMENT

FACSIMILE COVER SHEET

SALIWANCHIK, LLOYD & SALIWANCHIK

A Professional Association
2421 N.W. 41st Street
Suite A-1
Gainesville, FL 32606

Telephone (352) 375-8100
Facsimile (352) 372-5800

TO: Examiner Jeffrey Norman Fredman **FROM:** Frank C. Eisenschenk, Ph.D.

COMPANY: U.S. Patent Office, Art Unit 1655 **DATE:** March 25, 2002

FAX NO.: 1-703-872-9306

NO. OF PAGES:
(INCLUDING COVER SHEET) 5

SUBJECT/MESSAGE: U.S. Patent Application Docket No. GEN-T124X
GENES, PROTEINS AND BIALLELIC MARKERS RELATED OT
CENTRAL NERVOUS SYSTEM DISEASE
(Blumenfeld, *et al.*)
Serial No. 09/416,384; Filed October 12, 1999


THIS IS AN OFFICIAL DOCUMENT.
PLEASE DELIVER IMMEDIATELY.

Attachments: Supplemental Amendment Under 37 C.F.R. § 1.111
Marked-Up Version of Amended Claims

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on March 25, 2002.


Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL AMENDMENT
Examining Group 1655
Patent Application
Docket No. GEN-T124X
Serial No. 09/416,384

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Jeffrey Fredman, Ph.D.
Art Unit : 1655
Applicants : Marta Blumenfeld, Lydie Bougueleret, Ilya Chumakov,
Daniel Cohen, Laurent Essioux
Serial No. : 09/416,384
Filed : October 12, 1999
Confirm. No. : 6101
For : GENES, PROTEINS AND BIALLELIC MARKERS RELATED
TO CENTRAL NERVOUS SYSTEM DISEASE

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.111

In response to the Office Action dated November 19, 2001, and as a supplement to the response filed on February 19, 2002, please amend the above-identified application as follows:

In the Claims

Please substitute the following claims:

Claim 58. (Thrice Amended):

An isolated, purified, and recombinant glutamine repeat containing polypeptide comprising the amino acid sequence of SEQ ID NO:5.